Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study

被引：0
|
作者：
Aleš Linhart
Gabriela Dostálová
Kathy Nicholls
Michael L. West
Camilla Tøndel
Ana Jovanovic
Pilar Giraldo
Bojan Vujkovac
Tarekegn Geberhiwot
Einat Brill-Almon
Sari Alon
Raul Chertkoff
Rossana Rocco
Derralynn Hughes
机构：
[1] Charles University and General University Hospital in Prague,2nd Department of Internal Cardiovascular Medicine, First Faculty of Medicine
[2] Royal Melbourne Hospital and The University of Melbourne,Department of Nephrology
[3] Dalhousie University,Division of Nephrology, Department of Medicine
[4] University of Bergen,Department of Clinical Science
[5] Haukeland University Hospital,Nephrology and Rheumatology Unit, Department of Pediatrics
[6] Salford Royal,Department of Inherited Metabolic Disease
[7] Hospital de Dia Quiron,Centro de Investigación Biomédica en Red de Enfermedades Raras
[8] General Hospital Slovenj Gradec,Department of Internal Medicine
[9] University Hospitals Birmingham NHS Foundation Trust and University of Birmingham,Department of Diabetes, Endocrinology and Metabolism
[10] Protalix Biotherapeutics,Lysosomal Storage Disorders Unit
[11] Chiesi Farmaceutici S.p.A.,undefined
[12] Royal Free London NHS Foundation Trust and University College London,undefined
来源：
Orphanet Journal of Rare Diseases | / 18卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Prospective Results of Switching Enzyme Replacement Therapy from Agalsidase beta to Agalsidase alfa in the Canadian Fabry Disease Initiative Study
    West, Michael
    Bichet, Daniel
    Casey, Robin
    Clarke, Joe
    Sirrs, Sandra
    Flowerdew, Gordon
    LeMoine, Kaye
    MOLECULAR GENETICS AND METABOLISM, 2012, 105 (02) : S64 - S65
  • [42] A randomized, open-label study to compare the efficacy and safety of AT1001 and enzyme replacement therapy (ERT) in patients with Fabry disease and AT1001-responsive GLA mutations, who were previously treated with ERT
    Adera, Mathews
    Gladden, Allison
    Boudes, Pol
    MOLECULAR GENETICS AND METABOLISM, 2011, 102 (02) : S4 - S4
  • [43] Initial Results of an Open-Label Phase Ib Study to Evaluate Ilofotase Alfa in Adult Patients with Hypophosphatasia
    Seefried, Lothar
    Rutsch, Frank
    Nitschke, Yvonne
    Genest, Franca
    JOURNAL OF BONE AND MINERAL RESEARCH, 2024, 39 : 370 - 371
  • [44] Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naive or previously treated with imiglucerase
    Zimran, Ari
    Gonzalez-Rodriguez, Derlis Emilio
    Abrahamov, Aya
    Cooper, Peter A.
    Varughese, Sheeba
    Giraldo, Pilar
    Petakov, Milan
    Tan, Ee Shien
    Chertkoff, Raul
    BLOOD CELLS MOLECULES AND DISEASES, 2018, 68 : 163 - 172
  • [45] Results from a phase 3b, open-label, multicenter, CONTINUATION study of Rurioctocog Alfa Pegol for prophylaxis in previously treated patients with severe hemophilia A: Analysis by US age categories
    Mullins, E.
    Chowdary, P.
    Stasyshyn, O.
    Zhang, J.
    Engl, W.
    Tangada, S.
    HAEMOPHILIA, 2019, 25 : 48 - 49
  • [46] Long-term safety and efficacy of taliglucerase alfa in pediatric patients with Gaucher disease who were treatment-naive previously treated with immiglucerase
    Zimran, Ari
    Gonzalez-Rodriguez, Derlis Emilio
    Abrahamov, Aya
    Cooper, Peter A.
    Varughese, Sheeba
    Paz, Alona
    Brill-Almon, Einat
    Chertkoff, Raul
    MOLECULAR GENETICS AND METABOLISM, 2015, 114 (02) : S129 - S129
  • [47] Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study
    Wallace, Eric L.
    Goker-Alpan, Ozlem
    Wilcox, William R.
    Holida, Myrl
    Bernat, John
    Longo, Nicola
    Linhart, Ales
    Hughes, Derralynn A.
    Hopkin, Robert J.
    Tondel, Camilla
    Langeveld, Mirjam
    Giraldo, Pilar
    Pisani, Antonio
    Germain, Dominique Paul
    Mehta, Ankit
    Deegan, Patrick B.
    Molnar, Maria Judit
    Ortiz, Damara
    Jovanovic, Ana
    Muriello, Michael
    Barshop, Bruce A.
    Kimonis, Virginia
    Vujkovac, Bojan
    Nowak, Albina
    Geberhiwot, Tarekegn
    Kantola, Ilkka
    Knoll, Jasmine
    Waldek, Stephen
    Nedd, Khan
    Karaa, Amel
    Brill-Almon, Einat
    Alon, Sari
    Chertkoff, Raul
    Rocco, Rossana
    Sakov, Anat
    Warnock, David G.
    JOURNAL OF MEDICAL GENETICS, 2024, 61 (06) : 520 - 530
  • [48] Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in patients with Fabry disease: Twoyear interim results from the ongoing phase 3 BRIGHT51 openlabel extension study
    Bernat, John
    Holida, Myrl D.
    Longo, Nicola
    Goker-Alpan, Ozlem
    Wallace, Eric
    Deegan, Patrick B.
    Tondel, Camilla
    Eyskens, Francois J.
    Feldt-Rasmussen, Ulla
    Hughes, Derralynn
    Pisani, Antonio
    Rocco, Rossana
    Almon, Einat Brill
    Alon, Sari
    Chertkoff, Raul
    Warnock, David G.
    Waldek, Stephen
    Wilcox, William R.
    MOLECULAR GENETICS AND METABOLISM, 2023, 138 (02) : 16 - 16
  • [49] Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naive Fabry disease patients
    Tsuboi, Kazuya
    Yamamoto, Hiroshi
    BMC PHARMACOLOGY & TOXICOLOGY, 2017, 18
  • [50] First results of a head-to-head trial of pegunigalsidase alfa vs. agalsidase beta in Fabry disease: 2 year results of the phase 3 randomized, double-blind, BALANCE study
    Wallace, Eric
    Goker-Alpan, Wilcox
    Holida, Bernat
    Longo, N.
    Hughes, D.
    Giraldo, P.
    Molnar, M. J.
    Ortiz, Hopkin
    Tondel, C.
    Linhart, A.
    Deegan, Jovanovic
    Muriello, M.
    Barshop, Kimonis
    Vujkovac, B.
    Nowak, A.
    Geberhiwot, T.
    Pisani, A.
    Germain, D. P.
    Kantola, I.
    Knoll, J.
    Mehta, Ankit
    Waldek, Stephen
    Chertkoff, Raul
    Almon, Einat
    Alon, Sari
    Rocco, Rossana
    Warnock, David G.
    MOLECULAR GENETICS AND METABOLISM, 2023, 138 (02) : 132 - 133
12345